Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Kai Hübel, Mark Bower, Igor Aurer, Mariana Bastos‐Oreiro, Caroline Besson, Uta Brunnberg, Chiara Cattaneo, Simon Collins, Kate Cwynarski, Alessia Dalla Pria, Marcus Hentrich, Christian Hoffmann, M. J. Kersten, Silvia Montoto, José‐Tomás Navarro, Éric Oksenhendler, Alessandro Re, Josep‐María Ribera, Philipp Schommers, Bastian von Tresckow, C. Buske, M. Dreyling, Andrew Davies
Abstract
Non-Hodgkin lymphoma (NHL) remains the most common type of cancer and a leading cause of mortality in people who are living with human immunodeficiency virus (HIV).1 This is despite a marked decrease in the incidence of HIV-associated NHL (HIV–NHL) following the introduction of combination antiretroviral therapy (ART) in the mid-1990s.2 In contrast, the incidence of Hodgkin lymphoma (HL) increased slightly but has remained stable since 2000.1 Compared with the age- and gender-matched general population, the incidences of HIV–NHL and HIV-associated HL (HIV–HL) are increased ∼10- to 20-fold.